Posted by Michael Wonder on 28 Nov 2017
Ferring receives Swiss approval for Rekovelle, the first personalised fertility treatment using an approved dosing algorithm
27 November 2017 - Approval is based on a comprehensive clinical development programme (ESTHER), involving patients in 11 countries and over 2,000 treatment cycles.
Ferring Pharmaceuticals announced today that SwissMedic has approved Rekovelle (follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation or intracytoplasmic sperm injection.
Rekovelle is a new human recombinant follicle stimulating hormone and the first to use an approved individualised dosing regimen, based on a woman’s anti-Müllerian hormone level and body weight.
